You are viewing an expired study

This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please browse nearby listings below.

Click here to view additional nearby studies or search for clinical trials.

Ann Arbor, Michigan 48109

  • Sarcoma, Soft Tissue

Purpose:

The primary objective of this study is to assess the safety and effectiveness of ABT-510 in subjects with locally advanced or metastatic soft tissue sarcoma.


Criteria:

Inclusion Criteria A subject will be eligible for study participation if all of the following criteria are met: - The subject is at least 18 years of age. - The subject has histologically confirmed high grade locally advanced or metastatic soft tissue sarcoma (excluding Ewings sarcoma and chondrosarcoma) not amenable to surgery, radiotherapy or combined modality therapy with curative intent. - The subject must have at least one lesion with measurable disease by RECIST criteria using CT or MRI. - The subject has received no more than two cytotoxic treatment regimens, not including adjuvant therapy for sarcoma. - The subject has an Eastern Cooperative Oncology Group (ECOG) performance score of 0-1. - The subject is able to self-administer or has a caregiver who can reliably administer subcutaneous injections. - The subject must have adequate bone marrow, renal and hepatic function as follows: - Bone marrow: White blood cell count (WBC) greater than or equal to 3,000/mm3; Platelets; greater than or equal to 100,000/mm3; Hemoglobin greater than or equal to 9.0 g/dL; - Renal function: Serum creatinine less than or equal to 2.0 mg/dL; - Hepatic function: Bilirubin less than or equal to 1.5 mg/dL; AST and ALT less than or equal to 1.5 X the upper normal limit (ULN) unless liver metastases are present, then AST and ALT less than or equal to 5.0 x ULN. - The subject must not be pregnant or lactating and all subjects (male and female) must use a contraceptive method deemed acceptable by the investigator while in the study and for up to two months following completion of therapy. - The subject has voluntarily signed and dated an Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved consent prior to any study specific procedures. Exclusion Criteria A subject will be ineligible for study participation if any of the following criteria are met: - The subject has a history of or currently exhibits Central Nervous System (CNS) metastasis. Brain MRI within 28 days of enrollment is required to confirm absence of CNS metastases - The subjects is receiving therapeutic anticoagulation therapy. Low dose anticoagulation (e.g. low dose Coumadin) for catheter prophylaxis will be permitted; PT/PTT must be within normal limits. - The subject has a history of or currently exhibits clinically significant cancer related events of bleeding (e.g. hemoptysis). The subject has a recent history (within 4 weeks of Study Day 1) or currently exhibits other clinically significant signs of bleeding. - The subject has received any therapy for sarcoma including chemotherapy, radiotherapy or any investigational therapy. - The subject exhibits evidence of clinically significant uncontrolled condition(s) and/or is considered by the investigator to be unable to tolerate the proposed treatment or procedures. - The subject has history of other previous malignancies within five years, with the exception of:Adequately treated in situ carcinoma of the cervix uteri; Basal or squamous cell carcinoma of the skin. - The subject's life expectancy is less than 12 weeks.


Study is Available At:


Original ID:

M02-534


NCT ID:

NCT00061659


Secondary ID:


Study Acronym:


Brief Title:

Study Evaluating the Safety and Efficacy of ABT-510 in Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma


Official Title:

A Phase II Randomized Study Evaluating the Safety and Efficacy of ABT-510 in Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma


Overall Status:

Completed


Study Phase:

Phase 2


Genders:

Both


Minimum Age:

18 Years


Maximum Age:

N/A


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

Abbott


Oversight Authority:

United States: Food and Drug Administration


Reasons Why Stopped:


Study Type:

Interventional


Study Design:

Allocation: Randomized, Endpoint Classification:


Number of Arms:

2


Number of Groups:

0


Total Enrollment:

88


Enrollment Type:

Actual


Overall Contact Information

Official Name:Rod Humerickhouse, MD
Study Director
Abbott

Study Dates

Start Date:May 2003
Completion Date:April 2006
Completion Type:Actual
Verification Date:November 2007
Last Changed Date:November 28, 2007
First Received Date:June 2, 2003

Study Outcomes

Outcome Type:Secondary Outcome
Measure:Performance status
Time Frame:One year
Safety Issues:False
Outcome Type:Secondary Outcome
Measure:Overall survival
Time Frame:One year
Safety Issues:False
Outcome Type:Secondary Outcome
Measure:Response rate
Time Frame:One year
Safety Issues:False
Outcome Type:Primary Outcome
Measure:Progression free survival
Time Frame:One year
Safety Issues:False

Study Interventions

Intervention Type:Drug
Name:ABT-510 - Thrombospondin-1 mimetic

Study Arms

There are no available Study Arms

Study Agencies

Agency Class:Industry
Agency Type:Lead Sponsor
Agency Name:Abbott

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: April 03, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


This study is not currently recruiting Study Participants. The form below is not enabled.